Clinical Trial Update: Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus [Phase 4]

View source ↗

Summary

A Phase 4 study comparing reducing cyclosporine dose versus eliminating cyclosporine in kidney transplant recipients treated with sirolimus has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Graft-versus-host Disease

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Kidney Failure, Graft vs Host Disease | Phase 4 | Status: COMPLETED